Compare Altria Group Inc (MO) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Moderna, Inc. — how do they compare? Altria Group Inc trades at $67.94 (market cap $113.83B), while Moderna, Inc. trades at $135.83 (market cap $56.02B). The key difference: Altria Group Inc is far larger — about 2× Moderna, Inc.'s market cap, and Altria Group Inc pays a 6.51% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MO | MRNA | |
|---|---|---|
Market Cap | $113.83B | $56.02B |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $174.38 |
52-Week Low | $54.72 | $22.36 |
Enterprise Value | $136.04B | $52.17B |
Dividend Yield | 6.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $68.18, down 1.02% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock offers a high dividend yield of 6.45% following its 61st annual increase. Recent earnings show mixed quarterly results, with Q1 2026 beating expectations but Q2 2026 missing. Revenue remains stable around $20.1 billion (2025), with strong profitability margins, though net income declined to $6.95 billion in 2025 from $11.3 billion in 2024. Analyst consensus is bullish with a $68.50 price target.
MO presents a value opportunity with a low P/E of 14.35 and robust cash flows supporting dividends, but faces risks from regulatory lawsuits, declining cigarette volumes, and high debt levels. The stock's appeal hinges on dividend sustainability amid secular challenges in the tobacco industry.
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
